Deepblue Medical

Executive Summary

Deepblue Medical is a Shanghai-based medical device company founded in 2015, focusing on innovative cardiovascular interventions. The company develops minimally invasive devices, including stents and delivery systems, for treating coronary and peripheral artery disease. With a mission to offer high-quality, cost-effective alternatives to imported devices, Deepblue targets the growing Chinese healthcare market, where demand for affordable cardiovascular solutions is high. Currently in the commercial stage with 200–500 employees, the company has established a presence in China but faces competition from both domestic and international players. Its success hinges on differentiating through clinical efficacy, regulatory approvals, and price competitiveness. Deepblue's product portfolio likely includes drug-eluting stents and other interventional devices, though specific revenue data is not available. The company's future growth depends on expanding its product pipeline, securing regulatory clearances, and building distribution networks both domestically and potentially in emerging markets.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for next-generation drug-eluting stent70% success
• Q4 2026Positive 1-year clinical data for peripheral artery device60% success
• Q2 2026Strategic partnership with major Chinese hospital group50% success